troglitazone has been researched along with Squamous Cell Carcinoma of Head and Neck in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Squamous Cell Carcinoma of Head and Neck: The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saito, M | 1 |
| Fujita, Y | 1 |
| Kuribayashi, N | 1 |
| Uchida, D | 1 |
| Komiyama, Y | 1 |
| Fukumoto, C | 1 |
| Hasegawa, T | 1 |
| Kawamata, H | 1 |
1 other study available for troglitazone and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Troglitazone, a Selective Ligand for PPARĪ³, Induces Cell-cycle Arrest in Human Oral SCC Cells.
Topics: Cell Cycle Checkpoints; Cell Growth Processes; Humans; Hypoglycemic Agents; Ligands; Mouth Neoplasms | 2020 |